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Psychiatric disorders pose a major economic and health burden worldwide. Family and twin 
studies indicate strong genetic influences, with estimates suggesting substantial variance in liability 
is heritable. However known genetic risk variants for psychiatric disorders explain only a small 
fraction of the heritability estimated from twin studies, leaving the underlying genetic aetiology 
largely unknown. Given the wide range in prevalence, age at onsets, and gender ratios seen across 
psychiatric disorders it is reasonable to expect that different genetic architectures exist for each 
disorder. Thus the underlying genetic architecture of psychiatric disorders remains an open 
question, with large potential implications for identifying predictive genetic risk variants, 
redefining diagnostic criteria, and developing novel drug targets. 
This thesis focuses on combining epidemiological, genetic and environmental data to answer the 
questions surrounding the genetic architectures of psychiatric disorders. Initial analysis of 
epidemiological measures surprisingly identified that major depression was not under negative 
selection, a finding that was then confirmed through analysis of genotypic data. These results 
suggested the potential role of gene-environment interactions as an adaptive mechanism for 
variants contributing risk to depression, and were followed up by studies focusing on identifying 
such interactions. The conclusion of the thesis was though no gene-environmental interaction could 
be found to explain how the risk variants for major depression avoided negative selection, this was 
likely due in part to substantial gene-environment correlation in the reporting and experiencing of 
environmental risk factors in psychiatric disorders which would confound such analyses. Further 
these gene-environment correlations likely confound epidemiological associations identifying 
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1. Introduction  
1.1.1 Outline 
Psychiatric disorders pose a major economic and public health burden in developing and developed 
countries alike [Vos and others 2012]. Disorders such as schizophrenia, bipolar disorder, anorexia, 
autism and major depression are highly prevalent, with early mean ages of onset that lead to high 
levels of disability and morbidity, reduced reproductive fitness, and mortality. Family and twin 
studies indicate strong genetic influences, with estimates suggesting substantial variance in liability 
is heritable [e.g. Lee and others 2013b; Lichtenstein and others 2009]. This combination has long 
been noted as a paradox since natural selection should deplete genetic variation associated with 
reduced reproductive fitness [Keller and Miller 2006; Uher 2009]. This is further complicated as 
known genetic risk variants for psychiatric disorders explain only a small fraction of the heritability 
estimated from twin studies, leaving the underlying genetic aetiology largely unknown [Sullivan 
and others 2012]. Thus the underlying genetic architecture of psychiatric disorders remains an 
open question in the field, with large potential implications for identifying predictive genetic risk 
variants, redefining diagnostic criteria, and developing novel drug targets. This thesis will begin by 
outlining the nine major neuro-psychiatric disorders, then describing the relevant epidemiological 
and molecular genetic findings for each. The introduction will finish with summary of the 
publications which will compose the thesis. 
1.1.2 Summary of neuropsychiatric disorders  
1.1.2.1 Schizophrenia 
Schizophrenia is a psychotic disorder that affects around 1% of the population [McGrath and others 
2008], with a slightly higher prevalence in males than females. It is characterised by three main 
clusters of symptoms: positive symptoms such as hallucinations and paranoia; negative symptoms 
of anhedonia and catatonia; and disorganised thought processes with language and cognitive 





average slightly earlier for males [Faraone and others 1994]. It has been associated with urbanicity, 
migrant status, latitude, and season of birth [McGrath and others 2008]. Cannabis use has also been 
associated with a twofold increased risk of schizophrenia [Arseneault and others 2004]. 
Schizophrenia is associated with increased mortality [Joukamaa and others 2001], in part due the 
suicide related symptoms of the disorder. 
1.1.2.2 Bipolar disorder 
Bipolar disorder is a mood disorder, similar to schizophrenia in that it often includes psychosis and 
affects around 1% of the population [Bebbington and Ramana 1995]. However the positive and 
negative symptoms of bipolar disorder manifest in a more cyclical manner, and it lacks the same 
level of cognitive impairment. Individuals switch between episodes of manic behaviour to episodes 
of depression [APA 1994]. Two subtypes are often defined: bipolar disorder type 1 where there are 
clear manic and depressive episodes; and bipolar disorder type 2 where less clear hypomania 
episodes exist among periods of depression. Bipolar disorder has been associated with risk factors 
such as divorce, financial problems and job loss [Hosang and others 2012], though this may be 
driven by prodromal symptoms as these are all common side effects of the reckless sexual and 
financial behaviour that can accompany manic episodes. Unlike schizophrenia it does not show a 
robust association with lower socioeconomic status, with some studies even finding the opposite 
direction of affect [reviewed by Bebbington and Ramana 1995]. Interestingly, some studies have 
suggested an association with increased cognitive abilities in individuals with bipolar disorder 
[Gale and others 2013; MacCabe and others 2010]. Despite this, increased mortality exists and 
suicide is prevalent among those affected [Osby and others 2001]. 
1.1.2.3 Major depressive disorder 
Major depressive disorder (MDD), also known as unipolar depression, is the most highly prevalent 
psychiatric disorder (alongside the often co-morbid anxiety disorders) affecting ~15% of 





others 2005; Kessler and others 2003]. With most individuals experiencing recurrent episodes 
throughout life [Mueller and others 1999], it is now the 2nd leading cause of disability worldwide 
[Vos and others 2012]. It is a highly heterogeneous disorder, defined by reduced mood and energy, 
inability to experience enjoyment, changes to diet and sleep patterns, feelings of guilt or 
worthlessness, and suicidal thoughts [APA 1994]. Along with excess mortality and increased risk of 
suicide [Angst and others 2002], it is associated with worse clinical outcomes when co-morbid with 
health problems such as cardiovascular disease and cancer [Barth and others 2004; Satin and 
others 2009]. MDD can occur at any age with many life events associated with onset such as 
puberty, menopause, childhood maltreatment, childbirth, and divorce [Angold and others 1998; 
Freeman and others 2004; Greenwald and others 1989; Hosang and others 2012; Thapar and 
others 2012a].  
1.1.2.4 Autism 
Autism is a lifelong developmental disorder that is manifests in early childhood, with a prevalence 
of ~0.1% and found around 4 times as frequently in males than females [Fombonne 2005]. 
Prevalence has increased over recent decades though this is believed to be driven largely by 
improved ascertainment and broader diagnostic categories [Rutter 2005]. Symptoms fall into three 
broad categories: social impairment; reduced ability to communicate; and repetitive behaviour 
[APA 1994]. Autism is known to exist on a spectrum of severity and affected individuals will not 
necessarily have symptoms from all three categories, though severe impairment in one will of 
course impair the others. It is also often co-morbid with intellectual disability.  
1.1.2.5 Attention deficit hyperactivity disorder  
Attention-deficit hyperactivity disorder (ADHD) usually manifests in childhood, and is defined by 
developmentally inappropriate levels of hyperactivity, impulsiveness and inattention [APA 1994]. 
These symptoms are generally considered to give rise to three subtypes of ADHD: predominantly 





(low inattention, high hyperactivity), and combined type (high on both symptom dimensions). 
ADHD was initially believed to be a childhood disorder but is now recognised as frequently 
spanning from preschool age into adolescence and adulthood [Barkley 2008]. The prevalence of 
ADHD has been estimated at around ~5% in children and adolescents [Polanczyk and others 2007] 
and at around 2.5% in the adult population [Simon and others 2009]. It has been suggested that 
ADHD is associated with lower cognitive ability [Kuntsi and others 2004]. Associations with 
prenatal environment, such as maternal alcohol use or stress, have been reported but are not firmly 
established [Thapar and others 2012b]. 
1.1.2.6 Eating disorders 
Anorexia nervosa and bulimia nervosa represent the two most prominent eating disorders. 
Anorexia nervosa is characterised by extreme dieting and avoidance of food while bulimia nervosa 
is characterised by binge eating followed by purging, with a combined prevalence of around 1% and 
anorexia nervosa being the rarer of the two [Hoek and van Hoeken 2003; Hudson and others 2007]. 
Both have a much higher prevalence in women, usually with onset in the late teens [Lucas and 
others 1991]. Prevalence in men may be higher than estimated though due to underreporting 
[Strother and others 2012], and it is known that prevalence of anorexia varies greatly across 
countries and cultures [Hoek 2006; Pavlova and others 2009]. Anorexia is a particularly serious 
disorder due to its extremely high mortality rate, the highest of any psychiatric disorder [Sullivan 
1995; Zipfel and others 2000]. 
1.1.2.7 Substance abuse and addiction 
Substance abuse covers a large range of disorders that each vary greatly in their prevalence, usually 
as a result of the availability of the substance both in terms of geography and generation. The most 
common substances are those legally available such as alcohol and tobacco, with lifetime 
prevalences estimated at 17% and 24% respectively [Breslau and others 2001; Hasin and others 





that can be conceived on many levels that may not apply equally to every substance, such as the 
willingness to try new or illegal experiences, choice of social group and peers, ability to tolerate the 
substance, susceptibility to addiction in terms of personality, and susceptibility to addiction based 
on biological disposition to the substance. One of the more consistent findings from studies of 
addition and substance abuse is that males are at greater risk [Becker and Hu 2008]. 
1.1.2.8 Alzheimer’s disease 
Alzheimer’s disease is the most common form of dementia, accounting for up to 75% of cases [Lobo 
and others 2000]. It is characterised by rapid cognitive decline with an onset in late life, though 
early-onset forms exist. Symptoms include confusion, mood swings, language problems and 
memory loss. It is associated with a wide variety of risk factors [reviewed by Qiu and others 2009], 
including alcohol use, blood pressure, and poor social or mental activity throughout life. Ultimately 
cognitive functioning decreases until death.  
1.1.3 Expectations  
Clearly psychiatric disorders represent a wide variety of behavioural problems and impairments. 
They range greatly in prevalence from 0.1% to 15%, often appear much more frequently in women 
(e.g. anorexia and depression) or men (autism and substance abuse), and have onsets that range 
from just after birth to old age. Given the wide range in prevalence, age at onsets, and gender ratios 
seen across psychiatric disorders it is reasonable to expect that different genetic architectures exist 
for each disorder. In the next two sections I will evaluate the epidemiological and molecular 
evidence for the underlying genetics of these disorders, and build a consensus on where the causal 
variants exist. 
1.2 Genetic epidemiology 
Epidemiological studies can provide insight into the underlying genetics of any trait without 
requiring molecular genetic data. Twin and adoption studies can be used to test the relative impact 





individuals. Impact on fecundity gives us an insight into the selection on a trait, and so how likely it 
is that causal variants can survive in the population. Paternal aging is associated with increased 
burden of de novo mutations in the sperm, meaning an association with older fathers may reflect 
the importance of novel mutations. And lastly, non-random mating in the population with respect 
to a trait gives us insight into the likely distribution of causal variants. In this section I will expand 
on each of these epidemiological features and their bearing on psychiatric disorders. 
1.2.1 Twin studies 
The format of a twin study is intuitively appealing, as it naturally controls several variables. Twins 
are born at the same time in the same family, and hence should share a similar environment. They 
also share genes, 100% in identical or monozygotic twins (MZ) and 50% in terms of fraternal or 
dizygotic twins (DZ). These percentages refer of course to genetic differences relative to the general 
population (where one is 0% identical to an unrelated individual), as most of the human genome is 
unchanging across all individuals. This difference in genetic similarity between twins is due to MZ 
twins coming from a single fertilised egg splitting into two, while DZ come from two separately but 
simultaneously fertilised eggs.  A comparison of concordance rates between and within DZ and MZ 
twin pairs gives an insight into the role of genetics in the disease. If a disease was entirely genetic in 
nature, it would be expected that MZ twins were 100% concordant, and DZ twins 50% discordant 
reflecting their genetic differences. Even when that’s not the case, the level of genetic difference 
between MZ and DZ twins can be used to estimate genetic, shared and non-shared environmental 
factors through simple simultaneous equations when correlations of twins is known. This follows 
from the equations below. 
rMZ = h2 + c2 
rDZ = h2/2 + c2 





Here the rMZ reflects the correlation between MZ twins, which should be the heritability of the trait 
(h2) plus any shared environmental influences (c2). rDZ is the correlation between DZ twins which 
is the same as that of MZ, except reflecting only half the heritability as they share only half their 
genetic predisposition. As such, the correlations between MZ and DZ twins can be used to 
determine the heritability. The use of more advanced model fitting can then expand on these 
calculations, and provide confidence intervals for the estimates of genes and environment on the 
trait. 
The majority of psychiatric traits have high heritabilities, though range from 0.37-0.81. The highest 
heritabilities are in schizophrenia, bipolar disorder, ADHD and autism. In reviews of 12 twin studies 
of schizophrenia and bipolar disorders the heritabilities were estimated to be 0.81 and 0.75 
respectively [Smoller and Finn 2003; Sullivan and others 2003], though population studies give 
lower estimates at around 0.6 as well as reporting significant genetic overlap between them 
[Lichtenstein and others 2009; Wray and Gottesman 2012]. A meta-analysis of 20 studies of ADHD 
showed a heritability of 0.76 [Faraone and others 2005], though estimates have been found to be 
higher in children than in adults [Boomsma and others 2010; Larsson and others 2013]. A similar 
meta-analysis of 30 twin studies of autism estimated a heritability of 0.80 [Ronald and Hoekstra 
2011], with some evidence for substantial overlap in the heritability for severe autism cases as 
those on a more moderate spectrum [Robinson and others 2011]. Studies of Alzheimer’s disease 
and anorexia nervosa have suggested moderate heritabilities, of 0.58 and 0.56 respectively [Bulik 
and others 2007; Gatz and others 2006]. The heritability of substance abuse shows large ranges, 
perhaps due to the differing definitions of addiction across cultures and countries, or the 
availability of addictive substances. Alcohol addiction ranges from 0.48–0.66, nicotine from 33–
71%, cannabis 51–59%, and cocaine from 42 to 79% [reviewed by Agrawal and Lynskey 2006]. The 





studies [Sullivan and others 2000; Wray and Gottesman 2012], though some studies suggest it is 
substantially higher in early-onset recurrent cases [Levinson 2006; McGuffin and others 1996]. 
Note that these estimates reflect additive genetic effects, and so ignore gene-environment or gene-
gene interactions, dominant and recessive effects, and de novo mutations. They also rely on several 
assumptions, most importantly the equal environments assumption that MZ twins are not treated 
more similarly than DZ twins. Twin estimates also assume no assortative mating on the trait studies 
and that twins accurately represent this trait in the population, both of which may vary across 
disorders. Hence, twin estimates of heritability are not without some caveats when used as a 
benchmark for the role of genetics in any given disorder. 
1.2.2 Reproductive fitness 
Natural selection shapes the genetic architecture of any heritable trait. A genetic variant’s ability to 
stay at a given frequency is dependent on its impact on an organism’s reproductive fitness. The 
mutation-selection balance hypothesis suggests that deleterious genetic variants remain in the gene 
pool as new mutations are introduced at a pace equal to the selection against existing copies of the 
variant. An extension of this is the common disease common variant (CDCV) hypothesis where by a 
large number of risk variants with individually very small effects could escape selection. 
Antagonistic pleiotropy may also play a role, whereby genes that increase liability to a deleterious 
trait are beneficial under some circumstances, compensating for the negative selection in affected 
individuals. Selection shapes the genomic landscape of any trait, such as the number of risk alleles, 
their effect size, and their penetrance.  
Calculating the impact of psychiatric disorders on reproductive fitness is usually performed 
presenting a fecundity ratio (FR), comparing the fecundity of the disorder to that of the general 
population. Studies have largely focused on schizophrenia, and their results were meta-analysed in 





significantly reduced fitness (FR=0.39) while siblings showed a slight reduction (FR=0.96), with the 
effect being larger in males in both instances. They reported that parents of schizophrenic 
individuals showed no significant difference in FR, while one of the included studies reported that 
male offspring of schizophrenic individuals show reduced fecundity [Svensson and others 2007]. 
Outside of schizophrenia, bipolar disorder has not as consistently shown strong associations with 
reduced fecundity [MacCabe and others 2009; Mansour and others 2011; McGrath and others 
1999], though there is some evidence for reduced fecundity in autism, eating disorders and 
addictions [Uher 2009]. 
Some studies have focused on potential benefits of psychiatric risk variants, specifically creativity. 
Several early attempts were made to quantify the overlap of creativity and mental health, looking 
for an increased levels of creative professions in those affected by and the relatives of those with 
psychiatric disorders [Andreasen 1987; Herbert 1959; Jamison 1989; Juda 1949; Ludwig 1992; 
Post 1994]. For the most part these studies reported such an association, though were restricted by 
biased ascertainment and small sample sizes. In a more recent family study of 300,000 individuals 
[Kyaga and others 2011], those with bipolar disorder and healthy siblings of people with 
schizophrenia or bipolar disorder were overrepresented in creative professions, but not for 
individuals with or related to those with major depression. In a subsequent larger study, Kyaga and 
others [2013] found that, except for bipolar disorder, individuals in creative professions in general 
were no more likely to be diagnosed with psychiatric disorders than controls, though being an 
author was specifically associated with risk of psychiatric illness. Creative professions were found 
to be more frequent among ﬁrst-degree relatives of patients with schizophrenia, bipolar disorder, 
anorexia nervosa, and for siblings of those with autism. These findings have suggested a potentially 
shared heritability between creativity and psychiatric disorders, particularly bipolar disorder and 





1.2.3 Paternal age 
Paternal age has been associated with increased de novo mutations in a father’s offspring [Kong and 
others]. This is assumed to be due to the increased number of DNA replications that occur within 
sperm precursor cells compared to those that develop into eggs. This provides more opportunities 
for mutations to occur in male germ-line cells than those in females as they age. Thus an association 
with paternal age can provide insight into the role of de novo mutations in the genetic architecture 
of a trait. A further mechanism has been suggested, whereby those mutations that benefit sperm in 
their competition with each other to be passed on to the next generation are not necessarily those 
that benefit the offspring, and so may lead to deleterious traits [Goriely and others 2013]. This of 
course could maintain de novo mutations across generations. 
Early studies showed clear associations between both autism and schizophrenia and paternal age, 
specifically males fathering offspring over ~40, suggesting de novo mutations play a role in these 
disorders [Brown and others 2002; Durkin and others 2008; Hultman and others 2011; Malaspina 
and others 2001; Reichenberg and others 2006; Zammit and others 2003]. Bipolar disorder showed 
a weaker association, though it was stronger in early onset cases [Frans and others 2008]. Follow 
up studies showed that paternal age acts as a risk factor across generations, with grandpaternal age 
associated with autism even when paternal age is matched for [Frans and others 2013]. Maternal 
grandfather’s age also appears to contribute to risk in schizophrenia [Frans and others 2011], 
perhaps suggesting the role of mutations on the X chromosome. Two new studies have examined 
the impact of paternal age across a variety of disorders in Swedish and Danish populations 
[D'Onofrio and others 2014; McGrath and others 2014]. These showed paternal age effects across 
all disorders except eating disorders, including autism, ADHD, bipolar disorder, schizophrenia, 
suicide attempt, substance abuse, intellectual disability, and low educational attainment. Offspring 
of very young mothers and fathers were also found to be at increased risk, presumably due to 





parents may differ genetically in some way that predisposes their offspring to mental illness. For 
example, males that take longer to find partners and have children may be further along the 
schizophrenia spectrum. Thus some have argued that it is actually the father’s age at the birth of 
their first child rather than age at the birth of any individual child that is associated with risk [e.g. 
Pedersen and others 2014].  
1.2.4 Non-random mating 
Non-random mating can affect the genetic architecture of a trait in several ways. As mentioned 
above twin studies assume mating at random, as positive assortative mating (where individuals 
mate more often with similar individuals) can decrease estimates of heritability by increasing the 
genetic similarity of DZ twins above 0.5. Positive assortative mating also increases the number of 
homozygous individuals, pushing individuals to the extreme of the spectrum and potentially 
impacting the effects of selection. Positive assortative mating has long been shown with measures 
of personality [Zietsch and others 2011], though it remains unclear to what extent this results from 
cohabitation of partners. Increased cohabitation and assortative mating has been shown for severe 
psychiatric disorders, with very high levels reported for schizophrenia and bipolar disorder 
[Lichtenstein and others 2006; Thomsen and others 2013]. 
Positive assortative mating can lead to inbreeding defined as when individuals have a greater level 
of homozygosity in their genome than expected by chance, usually with reference to being identical 
by descent from a common ancestor. Inbreeding results in homozygosity across the genome, which 
can expose rare recessive variants that otherwise would not be expressed. Deleterious variants will 
be selected out of the population but, as the strength of negative and positive selection is greater on 
those of dominant effect, existing deleterious variants are more likely to be recessive. Hence 
inbreeding can expose deleterious mutations that otherwise would have been heterozygous. 
Inbreeding is associated with increased rates of illness, most commonly with reduced cognitive 





1.3 Molecular genetic findings 
Genetic studies of psychiatric disorders have rapidly expanded over the previous decades, mainly 
due to the huge changes in technology and cost that have revolutionised the field of genetics as a 
whole. This ranges from the first linkage studies of the co-segregation of disease and genotype in 
families, to genome-wide association studies comparing cases and controls for differences at 
hundreds of thousands or even millions of markers across the genome, to the more recent advances 
in whole genome sequencing. In this section I will give a brief description of each of these methods 
and their current findings in psychiatry. 
1.3.1 Linkage studies  
The first insights into the genetics of psychiatric disorders came from linkage studies. These focus 
on genotyping genetic polymorphisms within family pedigrees with multiple affected individuals. 
These studies look for the co-segregation of disease and genotypes across generations of family 
members, isolating the region in which the causal variant exists. Within this framework the results 
of multiple pedigrees can be combined to increase power, though this relies on the same mutation 
having an effect across families. These approaches had huge success with those disorders showing 
the classic Mendelian inheritance patterns of recessive or dominant effects, of which many include 
psychiatric aspects such as intellectual disability and autism [Betancur 2011]. For more complex 
manifestations of psychiatric disorders the results for linkage analyses were less impressive. Large 
scale meta-analyses of linkage studies for schizophrenia and bipolar disorder showed only one 
significant finding on chromosomes 2p12-q22.1 predisposing to schizophrenia [Lewis and others 
2003; Segurado and others 2003], later found again in a larger meta-analysis including some of the 
same studies [Ng and others 2009], and was unlikely to explain risk to a large proportion of cases. 
In contrast to this, Alzheimer’s disease showed clear linkage with regions surrounding rare 
autosomal dominant variants of unusually large effect in the amyloid beta precursor protein (APP), 





form of early-onset Alzheimer’s disease  [Bertram and Tanzi 2008]. Variants in the apolipoprotein E 
(APOE) were also identified that increased risk in late-onset Alzheimer’s disease [Corder and others 
1993], a gene that would reappear in genome-wide association studies along with several other 
common variants that contribute risk [Lambert and others 2013].   
1.3.2 Genome-wide association studies (GWAS) 
1.3.2.1 Methodology 
With the somewhat disappointing results for complex disorders from linkage studies, alternate 
methods were explored that moved away from the family design best suited for Mendelian 
disorders. The common disease common variant (CDCV) hypothesis was put forward, broadly 
suggesting that many high frequency but low effect variants might contribute to risk to complex 
disorders, thus explaining how they avoided negative selection, manifested in complex inheritance 
patterns, and allowed for genetic and phenotypic heterogeneity within disorders. To attempt to 
identify some of these common variants, genome-wide association studies (GWAS) were 
implemented. These restricted to looking at previously identified common variants 
(frequency>1%) across the genome, usually in the form of bi-allelic single nucleotide 
polymorphisms (SNPs). In the case of diseases, DNA samples from case and control groups are 
analysed using specially developed genotyping chips that contain anywhere from hundreds of 
thousands to millions of SNPs from across the genome. Each SNP is then tested to see if one variant, 
or allele, is significantly more frequent among cases than controls. Due to the co-inheritance of 
segments of the genome over generations, correlations between SNPs allow one to ‘tag’ local 
variation in the region. This means that while an association might be found with a SNP, it may 
actually be tagging a truly causal variant in the region rather than having a direct biological impact 
on risk. As such only relatively few SNPs need to be genotyped in order to capture a large amount of 





linkage disequilibrium, also allows for the imputation of additional SNPs not directly genotyped 
themselves but able to be filled in based on known correlations with those SNPs that have been.  
GWAS provided a novel method for identifying risk variants across the genome, without relying on 
prior biological knowledge of gene function needed to select a gene for candidate studies. This also 
had the perhaps unexpected outcome of identifying numerous variants in ‘gene deserts’, without 
any clear functional impact on gene expression or structure suggesting at a much more complex 
system.  The other benefit was that GWAS could move away from the pedigrees required for linkage 
analyses, removing some the constraints on recruitment and also alleviating concerns that the 
ascertainment of familial cases might give insight into a different aetiology compared to sporadic 
cases. The weakness of the GWAS method was the risk of false positives, the cause being twofold. 
First, the wide recruitment of unrelated cases and controls runs the risk of subtle population 
differences between the two groups e.g. an excess of cases from at risk minority groups. This can 
lead to the identification of SNPs that while highly significant are informative only of ancestry, not 
the underlying biology of the disease. To account for this many studies restrict recruitment to 
ethnically homogenous groups, e.g. where participants reported themselves as white with all 
grandparents were born in the UK. To account for more subtle influences of population 
stratification, principal component analysis is frequently used to construct covariates capturing 
correlations of SNPs across the genome. These have been shown to clearly capture subtle ancestry 
differences with high accuracy [Novembre and others 2008]. The second source of false positives is 
more intrinsic to the nature of GWAS, with the testing of hundreds of thousands of markers leading 
to a very large number of SNPs expected to be significant at p<0.05 by chance (since this reflects a 1 
in 20 chance of the result occurring at random). To account for this a genome-wide significance 
level is often implemented at p=5E-8, estimated to account for the number of tests across the 





sizes are required to have adequate power to detect true effects, and a lower threshold is often used 
to identify SNPs at a suggestive significance to be taken forward for replication. 
1.3.2.2 Findings 
The initial GWAS in psychiatric disorders showed little to no success in identifying causal risk 
variants, unlike some somatic disorders [Wellcome Trust Case Control Consortium 2007].There 
were several exceptions to this, mostly in those psychiatric disorders where the biology was better 
understood. As mentioned the first GWASs into Alzheimer’s disorder quickly identified novel 
findings [Harold and others 2009; Hollingworth and others 2011; Lambert and others 2009; Naj 
and others 2011] despite relatively small sample sizes, including regions originally identified in 
candidate studies. GWAS of nicotine addiction also identified variants in nicotine receptor genes 
[Tobacco and Genetics Consortium 2010; Liu and others 2010; Thorgeirsson and others 2010] and 
for alcohol usage and dependence in alcohol dehydrogenase genes previously associated with 
ability to break down alcohol [e.g. Bierut and others 2012; Gelernter and others 2014]. 
While the initial disappointing results for most disorders was taken by some as evidence against 
the common disease common variants hypotheis, efforts were made by researchers to pool samples 
together into meta-analyses (or mega-analyses, with data analysed together) in order to increase 
power to detect SNPs of small effect [e.g. Purcell and others 2009]. This approach came to fruition 
most clearly with the Psychiatric GWAS Consortium (later the Psychiatric Genomics Consortium or 
PGC), which in 2011 published two GWAS on schizophrenia and bipolar disorder [Ripke and others 
2011; Sklar and others 2011]. The schizophrenia analysis combined 9,394 cases and 12,462 
controls from 17 studies and identified 7 risk loci for schizophrenia, including the major 
histocompatability complex (MHC) region that had previously been suggested in earlier candidate 
gene studies [McGuffin 1979]. The analysis of bipolar disorder identified two genome-wide 
significant loci in a sample of 7,481 cases and 9,250 controls from 12 studies. Both studies were 





the direction of effect was concordant within the discovery and independent replication datasets 
suggesting that with greater sample sizes some of these SNPs might reach genome-wide 
significance. A future meta-analysis of the PGC schizophrenia studies with several thousand 
additional cases and controls from Swedish samples would prove this true [Ripke and others 
2013a], identifying 13 more loci at genome-wide significance. A similar trend was seen in 
Alzheimer’s disease, with the pooling of samples into the GERAD consortium of 17,008 cases and 
37,154 controls to identify 20 associated loci [Lambert and others 2013], and as previously 
mentioned GWAS to some extent verified previously known variants from linkage studies. These 
results showed that once large enough sample sizes had been achieved, GWAS could identify novel 
associations and insights into the aetiology of psychiatric disorders.  
Not all large GWAS collaborations yielded such successes though. The PGC analysis of MDD failed to 
identify any genome-wide significant associations, and the concordance between discovery and 
replication samples for the top SNPs was much weaker, despite a similar sample size of 9,240 cases 
and 9,519 controls [Ripke and others 2013b]. Similar negative findings were found for ADHD and 
autism [Neale and others 2010; Smoller and others 2013], though here the sample sizes were 
smaller. However the success in schizophrenia motivated the collection of genotyped samples for 
new disorders, both within and without the PGC, including anorexia nervosa [Boraska and others 
2014; Wang and others 2011], cannabis use [Verweij and others 2013], Tourette’s [Scharf and 
others 2013], OCD [Stewart and others 2013] , anti-social behaviour disorder [Tielbeek and others 
2012], anxiety [Trzaskowski and others 2013], insomnia [Byrne and others 2013] and borderline 
personality [Lubke and others 2013]. Though most of these GWAS led to negative findings, a few 
successes stand out, namely post-traumatic stress disorder [Xie and others 2013] and in a very 
large meta-analysis of educational attainment [Rietveld and others 2013], as a proxy for cognitive 
functioning.  Despite the current abundance of negative findings, increasingly large samples seem 





1.3.3 Polygenic methods  
For the most part even where genome-wide significant associations have been identified in GWAS, 
they still explain only a very small proportion of the variance in risk for psychiatric disorders. 
Hence several methods have been designed to make use of GWAS data to estimate the amount of 
variance explained when the effects of variants across the genome are combined. One of these was 
alluded to briefly in the above section, whereby concordance between the direction of effect in the 
discovery sample’s top SNP associations is compared to the direction of effect in the replication 
sample (known as a sign test). However most of the methods discussed here focus not on the top 
SNPs from a GWAS but on all available SNPs. This is due to the stringent threshold for genome-wide 
significance and the presumption that many truely causal SNPs of small effect might not meet it, yet 
their cumulative effect could explain a large amount of the variance in risk. 
1.3.3.1 Polygenic risk profile scoring 
The first method to be discussed is polygenic risk profile scoring (PRS). This is similar to a sign test 
in that it requires a discovery sample and a replication (or target) sample. In the discovery sample a 
GWAS is performed, defining the risk allele and effect size for each SNP. In the target sample the 
number of risk alleles an individual carries is summed into a score, with each SNP weighted by its 
effect size. This is then used as a predictor of risk to determine how much of the variance between 
cases and controls is explained by the PRS. The PRS is often defined using various p-value 
thresholds for the inclusion of SNPs from the discovery GWAS, e.g. four scores using SNPs with 
p<0.001, p<0.05, p<0.2, and p<0.5. As more SNPs are included, the greater the likelihood that all 
SNPs of true effect will be captured. However including more SNPs also includes more with no true 
effect and so adds noise, causing a levelling off of the amount of variance explained. The first 
application of PRS was in the International Schizophrenia Consortium, which showed ~2% of the 
variance could be explained across samples [Purcell and others 2009]. They were also able to show 
that PRS for schizophrenia could also predict bipolar disorder vs. controls with a slightly reduced 





schizophrenia was predicted by PRS [Ripke and others 2011], 3% for bipolar disorder [Sklar and 
others 2011], and 0.6% for MDD [Ripke and others 2013b]. Cross disorder analysis also showed 
that schizophrenia, bipolar disorder and MDD PRS all predicted across each other, with some more 
weakly predicting into autism and ADHD [Smoller and others 2013]. More complex Bayesian 
approaches to PRS have also estimated the number of independent risk variants for schizophrenia 
to be between 6,300–10,200, accounting for 32% of the variance in risk [Ripke and others 2013a]. 
1.3.3.2 Genomic-relatedness-matrix residual maximum likelihood analysis 
An alternate polygenic method, genomic-relatedness-matrix residual maximum likelihood analysis 
(GREML), was designed not for prediction of risk but to estimate what proportion of variance is 
captured by SNPs, thus giving a heritability estimate based on known genetic variants rather than 
from twin models [e.g. GCTA, developed by Yang and others 2011]. This method works by 
estimating the relatedness of all pairs of individuals in the dataset, and testing how much of the 
similarity in phenotype within pairs is accounted for by genetic similarity (relatedness). 
Relatedness here is defined as the proportion of the genome for which they have the same 
genotypes. It is important to note that the results of this analysis do not reflect the true heritability 
of a trait, as it only includes that heritability captured by the included SNPs while usually ignoring 
the role of rare or structural variation. It does however act as a benchmark for the maximum 
amount of risk detectable in an infinitely powered GWAS. An analysis within the PGC showed 
schizophrenia, bipolar disorder, MDD, ADHD, and autism all had relatively similar SNP-heritabilities 
at around ~20-25%, with the highest in ADHD (28%) and the lowest in autism (17%) [Lee and 
others 2013b]. GREML analysis can also be applied using bivariate models to estimate the co-
heritability of two disorders captured by SNPs, with the key benefit of not requiring individuals to 
have data on both phenotypes [Lee and others 2012]. MDD, schizophrenia and bipolar disorder 
showed highly significant co-heritabilities at around 10-15%, as well as slightly lower co-





analyses suggested that while a large proportion of the heritability consistently came from genes 
annotated as related to brain function, it also unexpectedly showed that within disorders different 
studies did not overlap in their genetics entirely e.g. the heritability of MDD in study 1 might only 
show a co-heritability of 60% with the heritability of MDD in study 2, presumably due to 
heterogeneity across studies. Other studies have shown significant heritabilities for Alzheimer’s 
(24%) [Lee and others 2013a] and Tourette’s and OCD (58% and 37%, with significant genetic 
correlation between them) [Davis and others 2013]. Other studies have shown that SNP-heritability 
substantially overlaps across populations [de Candia and others 2013; Yang and others 2013]. 
These findings broadly are in agreement with those from PRS studies, suggesting that common risk 
variants contribute substantial risk to psychiatric disorders despite the individual risk variants not 
yet being identified. Presumably this is due to a large number of variants of small effect, with the 
results suggesting that these variants contribute non-specific risk to psychiatric disorders in 
general rather than uniquely to one disorder.  
1.3.3.3 Runs of homozygosity 
The last polygenic method discussed here is the analysis of runs of homozygous markers across the 
genome. An excess of homozygosity across the genome reflects inbreeding, whether through more 
recent events, such as consangous marriages, or among more distant ancestors. It has been shown 
that by looking for sections of consecutive homozygous markers more accurately captures 
inbreeding over using simply percentage of genome is homozygous [Keller and others 2011]. 
Homozygosity not only reflects inbreeding but also exposes recessive variants, those that have a 
non-additive effect with number of alleles an individual carries. A fully recessive variant is only 
expressed when an individual carries a copy on both chromosomes, though variants with partially 
recessive effects exist. As this can hide deleterious alleles from being expressed, natural selection 
acts to increase the frequency of dominant beneficial alleles and selects out more quickly dominant 





Hence if these runs of homozygosity (ROH) are associated with a trait or disorder, it is evidence 
that the disorder has experienced historical selection against it. This informs both on its negative 
effect on ancestral human reproductive fitness, and that a recessive model of risk may be more 
appropriate when attempting to identify risk variants. Such an association has been suggested by 
several studies of psychiatric disorders, most prominently in schizophrenia [Keller and others 
2012], intellectual disability and autism [Gamsiz and others 2013]. However, due to the very small 
effect sizes expected future studies require very large sample sizes in order to identify such an 
association [Keller and others 2011]. 
1.3.5 Whole Genome Sequencing  
In the last few years GWAS have been followed up by whole-genome sequencing (WGS). This 
approach has become more popular as the cost has decreased and next generation technologies 
have been developed. While GWAS relies on using common genetic markers to tag local variation, 
WGS allows for the identification of the causal variant directly. It also allows for the analysis of rare 
variants, in particular de novo mutations that could never be found on a genotyping chip of known 
variants. The downside of this approach is that the sheer number of variants to test increases 
dramatically. This has several draw backs: by increasing the computational burden of analyses; by 
inflating the burden of multiple testing and so the threshold for significance; by including not just 
common variants but also rare variants where the power to detect significance is greatly reduced; 
and by not restricting to known variants and so increasing the risk of a incorporating sequencing 
errors. As such many methods for analysing WGS data have focused on analysing burden of rare 
variants across segments of the genome, or have returned to the format of linkage studies by 
leveraging pedigree information to investigate co-segregation of disease and variant. These 
methods often have led to a focus on variants within genes, where their impact on the protein can 
be estimated and weighted for. As such some studies have focused on exome sequencing, targeting 





again has led the way with the discovery of several variants in exome and genome sequencing 
studies [Guerreiro and others 2012; Pottier and others 2012]. And within other psychiatric 
disorders, the results are again less impressive to date. The most recent large scale analysis of 2,536 
schizophrenia cases and 2,543 controls’ exome sequences suggested cases showed a polygenic 
burden of disruptive mutations, particularly concentrated in previously associated gene pathway 
[Purcell and others 2014]. Several studies of exome sequencing in autism came out in 2012, 
implicating rare and de novo mutations though unable to identify individual loci definitively 
[Iossifov and others 2012; Neale and others 2012; O'Roak and others 2012; Sanders and others 
2012]. These studies, as well as for schizophrenia [Fromer and others 2014], found an excess of de 
novo mutations amongst cases, particularly those with later paternal ages, providing evidence that 
these novel mutations may play a crucial role in psychiatric disorders.  
1.3.6 Structural variation 
As well as point mutations in the genome, where one base pair is replaced by another, there is the 
possibility of structural variation where base pairs or segments of the genome are deleted or 
duplicated. While many forms of structural changes exist, current genetic research has focused on 
larger copy number variants (CNV) that can be de novo or remain in the population as CNV 
polymorphisms. Schizophrenia has been seen as highly prevalent within the syndromic CNVs, such 
as 22q11 cardiofacial syndrome. As well as these syndromic effects, several large and rare CNVs of 
large effect are known to convey risk to schizophrenia, though also numerous other disorders such 
as autism, intellectual disability and epilepsy [reviewed inSullivan and others 2012]. Intellectual 
disability and autism both have a high burden of large structural variants or in a large number of 
cases [Folstein and Rosen-Sheidley 2001; Sanders and others 2011; Vorstman and others 2006] , 
sometimes established as the cause such as in the case of fragile X syndrome. As well as the 
identification of large CNVs, GWAS data can be used to identify smaller CNVs. This is done by 





ratio of heterogeneity. These methods have been used to look at burden of CNVs across the genome 
for various psychiatric disorders. Such an association established in several studies of 
schizophrenia [Szatkiewicz and others 2014; Walsh and others 2008; Xu and others 2008], ADHD 
[Williams and others 2012; Williams and others 2010; Yang and others 2013] and autism [Pinto 
and others 2010], particularly among de novo CNVs and those in genic regions [Kirov and others 
2012; Szatkiewicz and others 2014]. The results for bipolar disorder are more mixed [Grozeva and 
others 2010; Malhotra and others 2011; McQuillin and others 2011; Priebe and others 2012; Zhang 
and others 2009], while only one association for MDD with CNV burden has been reported [Rucker 
and others 2013]. Alzheimer’s again shows concordance across different methods with associations 
with variants across the APP region [McNaughton and others 2012; Rovelet-Lecrux and others 
2006].  
1.4 Summary and outline of thesis 
1.4.1 State of psychiatric genetics findings 
These molecular and epidemiological findings have started to give insight into the genetic 
architecture of psychiatric genetics. While individual risk variants are still relative few for most 
disorders, a few patterns have started to emerge. Structural, rare and common variants for 
schizophrenia, bipolar disorder and autism appear to cluster in genes with brain function. 
Polygenic approaches have shown that common variants account for around ~15-30% of the 
variance in psychiatric disorders, approximately a third or half of the heritability. This suggests that 
as GWAS studies increase in size they will have sufficient sample size to identify many more 
common variants of small effect. Studies of cumulative burden of rare and de novo structural and 
point mutations across the genome also suggest that larger samples will yield associations with 
individual variants. Epidemiological evidence for paternal age effects suggests these approaches 
may have the greatest success for schizophrenia and autism. However progress may depend on the 





methodologies for analysing very rare variants. Hopefully the disorder with the greatest success, 
Alzheimer’s disease, will act as a template whereby rare, common and structural variants converge 
onto specific regions, presenting biological insight and drug targets. 
This success will no doubt come through the ability to generate larger and larger sample sizes for a 
variety of disorders, something that is already occurring through cheaper genotyping/sequencing 
technologies and the acceptance of the need for international collaborations. In the meantime, 
several approaches can make use of existing data to gain a better picture of the underlying genetics 
of psychiatric disorders. My thesis will make use of six papers across three areas of research to gain 
novel insight into the genetic architecture of psychiatric disorders. The following sections will 
outline the contents and objectives of each. 
1.4.2 Impact on reproductive fitness 
In the first section of my thesis I will examine two ways in which psychiatric disorders can impact 
reproductive fitness and behaviour. The first paper, “Fecundity of patients with schizophrenia, 
autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected 
siblings” [Power and others 2013b], focuses on a systematic analysis of the impact of psychiatric 
disorders on fecundity, as measured by number of children in both those diagnosed with a disorder 
and unaffected relatives. As discussed above this has huge impact on how causal variants are 
maintained in the population, and so the distribution of frequencies and effect sizes. The second 
paper “A recessive genetic model and runs of homozygosity in major depressive disorder” focuses 
on major depression following the results of the previous paper, looking for molecular support for a 
lack of negative selection on depression in the Psychiatric Genomics Consortium’s sample of over 
9000 each of MDD cases and controls with genome-wide association data [Power and others 
2014a]. Together they paint a picture of where we might expect to identify causal variants in 





1.4.3 Gene-environment interactions  
Following the results of the previous section showing potential evidence for beneficial effects of 
genetic risk variants for MDD, the next section will focus on gene-environment interactions and 
whether they could provide an answer to why these variants appear to sometimes increase an 
individual’s fitness. It is clear that some individuals succumb to environmental risk factors while 
others do not. Whether risk variants for a disorder predispose individuals only in certain 
environments seems plausible, though the evidence for such gene-environment interactions is often 
highly contested.  
In this section I first test the ‘Mismatch hypothesis’ which suggests environmental risks may 
interact with each other differently based on an individual’s genetic background of ‘plasticity’ 
variants in a paper titled “The interaction between child maltreatment, adult stressful life events 
and the 5-HTTLPR in major depression” [Power and others 2013c]. In a second paper, I look not at 
testing for gene-environment interactions but to stratify cases and controls into equivalent levels of 
environmental stress exposure, in a paper “Genome‐wide association analysis accounting for 
environmental factors through propensity‐score matching: Application to stressful live events in 
major depressive disorder” [Power and others 2013a]. Both approaches aim to move beyond the 
conventional gene-environment interaction analysis, which has to date produced limited returns. 
1.4.4 Untangling genetic from environmental risk 
Following from the findings of the previous section, I explore how the relationship between 
environmental and genetic risk factors is complicated by the possibility not just of interactions but 
also correlations. There are several ways in which this can occur, with individuals selecting their 
own preferred environments and having their environments react to them. This can contribute to 
gene-environment correlation, particularly with respect to behavioural traits, and creates a 
problem for disentangling the causation of associations in the epidemiology of psychiatric trait. In 





genetic variants” [Power and others 2013d] and “Genetic predisposition to schizophrenia 
associated with increased use of cannabis” [Power and others 2014b], I test for an underlying 
heritability for the known ‘environmental’ psychiatric risk factors of stressful life events and 
cannabis use, and look at how this heritability may overlap with the heritability of psychiatric 
disorders themselves. 
1.4.5 Conclusion 
Psychiatric genetics is on the verge of major advances, largely due to the massive increase in 
available data. As yet there are still many unanswered questions about the underlying aetiology of 
these disorders, such as their impact on reproductive fitness, the extent to which we can dissect 
heterogeneity within disorders through genetics, and the complex relationships between genes and 
environment. Overall this thesis will combine epidemiological, genetic and environmental data to 






2. Fecundity of patients with schizophrenia, autism, bipolar disorder, 





































































































Supplementary Figure 1: Manhattan plot from p-values of genome-wide association analysis of major 
depression under a recessive model.  
 
Supplementary Figure 2: QQ plot of p-values from genome-wide association analysis of major 















Percentage of recurrent cases 0.01 Controls 0.84 
German study binary variable 0.58 Cases 0.02 
US study binary variable 0.41 Controls 0.06 
Australian study binary variable 0.04 Controls 0.59 
Binary variable for if study was genotyped on Illumina 0.45 Cases 0.05 
Binary  variable for if copy number variant probes were available on 
the genotyping platform 0.01 Controls 0.79 
Mean FROH 0.18 Cases 0.25 







4. The interaction between child maltreatment, adult stressful life events 
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6. Estimating the heritability of reporting stressful life events captured by 




























































Psychiatric disorders reflect a wide range of illnesses that, while showing substantial aetiological 
and diagnostic overlap, vary greatly in prevalence, symptoms, onset, and heritability. The work 
presented in this thesis began by looking at the impact of these disorders on reproductive fitness, to 
understand if they are likely to undergo the same selection pressures and so have similar 
underlying genetic architectures. This identified that depression was not under negative selection, a 
finding that was then explored through molecular data. These results suggested the potential role of 
gene-environment interactions as an adaptive mechanism for variants contributing risk to 
depression, and were followed up by studies focusing on identifying such interactions. The 
conclusion of the thesis was though no gene-environmental interaction could be found to explain 
how the risk variants for major depression avoided negative selection, this may be due to 
substantial gene-environment correlation in the reporting and experiencing of environmental risk 
factors in psychiatric disorders which would confound such analyses. A more detailed discussion 
follows of the findings and how they relate to each other. 
8.2 Overview of Findings 
The first paper of the thesis examined epidemiological data from Sweden for evidence of the 
selection on psychiatric traits [Power and others 2013b]. The most striking finding of this analysis 
was that affected males showed a much greater reduction in fecundity than affected females, 
suggesting that psychiatric illness impacts the fitness of men to a greater extent and there may be 
sex-specific selection on the causal genetic variants. On an individual disorder basis, autism and 
schizophrenia showed the expected large reduction in fecundity within patients suggesting that 
genetic variants that predispose to risk are under negative selection and are maintained by de novo 
mutations. Anorexia, substance abuse and bipolar disorder showed a moderate reduction in 





distinction between bipolar disorder and schizophrenia in the literature of molecular studies of 
these disorders [Sullivan and others 2012], with a greater role of novel mutations observed in 
schizophrenia.  Surprisingly, only a very small reduction was seen in depression patients which was 
further restricted to affected males not females. Even more surprisingly this reduction was more 
than compensated by the observed increase in fecundity in the siblings of affected individuals, 
suggesting that having certain combinations of the risk variants and environments for depression 
could be beneficial to an individual’s fitness. This finding was based on modern levels of fecundity 
which may be confounded by a number of factors, such as the effects of hospitalisation and 
treatment, modern stigma of the disorders, and the use of contraceptives, which may give estimates 
of selection on these disorders that do not relate to historical levels throughout human evolution. 
This is an important distinction as the genetic architecture of traits is defined by selection over 
previous generations, rather than selection in the current generation. In the second paper of this 
thesis, it was supported by findings from a molecular study of 9 studies of major depression looking 
for an association with runs of homozygosity (ROH) [Power and others 2014a],which can be used 
to infer the impact of selection on a trait over previous generations. Inbreeding, as captured by 
ROH, exposes recessive variants, and an excess of recessive variants in association with a trait 
suggests that it has previously experienced negative selection. This is due to the fact that selection 
rapidly removes dominant deleterious mutations but both cannot as easily act on recessive variants 
and acts to select dominant advantageous variants. ROH were not associated with major depression 
status across a meta-analysis of nine studies, suggesting overall there was no evidence for negative 
selection on depression over previous generations.  
However individual studies within this meta-analysis showed significant associations with ROH and 
significant heterogeneity across studies was observed, seemingly driven in part by the country the 
study took place in. This result and the findings from the epidemiological study, as well as previous 





environmental backgrounds determining the impact of variants predisposing to MDD on fecundity. 
To examine this idea further, two studies were performed within the RADIANT consortium where 
access to detailed environment and genotype data was available. In the third paper of this thesis the 
interaction between childhood and adult environmental adversity was examined [Power and others 
2013c], testing the mismatch hypothesis of depression whereby individuals are primed as children 
for a stressful or non-stressful environment in adulthood and the disorder manifests when this 
expectation is not met [Nederhof and Schmidt 2012] . This hypothesis also puts forward that some 
individuals show plasticity and can be ‘programmed’ by early experiences to develop behaviours 
that will maximise future gain (e.g. calibrating their level of anxiety to avoid harm but not be overly 
conservative), while other individuals show no plasticity but are more robust to environmental 
stressors.  In this model of depression, the risk variants for depression would not always confer risk 
but rather are likely ‘plasticity’ markers of an individual’s predisposition for priming in childhood 
or potentially their predisposition to misjudge the level of stress they should be primed for. 
However no evidence for the mismatch hypothesis was found in the interaction of environmental 
stressors across life or with a potential plasticity genetic risk variant (5-HTTPLR). This may have 
been due to the severity of the environmental stressors used, particularly the level of childhood 
maltreatment which was often severe, or the very improbable likelihood of success from using a 
candidate gene over an established replicated variant (which are currently lacking for depression) 
[Ripke and others 2013b]. The fourth paper of this thesis focused on a novel approach to 
indentifying novel variants for major depression not by looking for their interaction with 
environmental stressors, but by matching cases and controls on environment [Power and others 
2013a]. In this analysis we observed no such variants, likely due to the large reduction in sample 
size that resulted from including only cases and controls with overlapping levels of stressful life 
events and the large discrepancy in their distributions in the two groups. In fact we observed a 





on their reported number of stressful life events, suggesting that even adding more samples was 
unlikely to increase our chances of identifying novel genetic variants. 
This deflation of associations may have been due to overcorrecting if the genetics of depression 
correlates with the reporting of stressful life events, or the genetics of reporting or experiencing 
such events. Stressful life events are themselves are known to be heritable [Billig and others 1996; 
Kendler and others 1993; Plomin and others 1990], as their likelihood of occurring is to some 
extent the result of an individual’s personality and actions. In the last two papers of thesis we 
explored this in two ways. The fifth paper of the thesis focused on looking at the heritability of 
stressful life events, or at least the heritability of reporting such events, making use of genome-wide 
heritability estimation methods to calculate the heritability of a trait directly captured by molecular 
data rather than from an adoption or twin design [Power and others 2013d]. Such methods work by 
using genetic data to estimate the very low levels of relatedness between each pair of ‘unrelated’ 
individuals within the sample, as estimating to what extent this relatedness explained variation in 
phenotype. This found substantial heritability in stressful life events captured by the common 
variants observed, that appeared to be driven primarily by an individual’s level of neuroticism. This 
itself is a heritable trait and suspected to overlap with depression in aetiology and definition, 
suggesting that those who are predisposed to being more depressed report more stressful life 
events. This may reflect a difference in perception of one’s environment that may precede the onset 
of the disorder and confound the analysis of triggers of depression, and highlights the importance 
of having rigorously defined and recorded environmental measures due to the possibility of 
unreliable reporting. The sixth and last paper of this thesis showed that this gene-environment 
correlation is not restricted to the reporting of stressful events but also observed for traits such as 
drug use, showing that healthy individuals in the general population with a greater genetic 
predisposition to schizophrenia as defined by polygenic scoring are more likely to use cannabis 





wide association study to define which variants are more common in cases than controls 
(regardless of significance) and then counting them up in each individual of a independent sample. 
This provides each individual with a polygenic risk score which can be used to predict the same 
trait or other traits to test for genetic overlap, in this case taking the results from the most recent 
genome-wide association study of schizophrenia [Ripke and others 2013a] to test their cumulative 
association with cannabis use. This showed an association with both whether an individual had 
ever used cannabis and within users their quantity of use, but not with age at first use which had 
previously also been suggested to influence risk of psychosis. Given the well established association 
between cannabis use and risk of schizophrenia from epidemiological work [Arseneault and others 
2004; McGrath and others 2010], this gene-environment correlations are important for how we 
identify and define environmental risk factors for psychiatric disorders. That is not to say that every 
gene-environment correlation removes the risk from environment, in fact the risk could still be 
mediated by the environment whereby individuals are genetically predisposed to seek out 
environments that are deleterious. Distinguishing situations where genes predispose individuals 
pleiotropically to both a disease and an environment through independent pathways (and so 
preventing the environment does not reduce disease risk), from situations where genes predispose 
individuals to an environment that increases the risk of a disease (and so mediates the pathway to 
risk) will be crucial for understanding when environmental interventions will yield success or not. 
Understanding how to integrate such gene-environment correlations into the analyses of gene-
environment interactions will be crucial to developing methods to better identify the latter, and 
understand how genes and environment come together to predispose individuals to risk of a 
disorder.  
8.3 Future directions 
There are several potential areas of research that expand upon this work. Primarily is the wider 





estimates such as those available from GCTA [Purcell and others 2009; Yang and others 2011], to 
gene-environment interaction studies. These allow researchers to side step the main problem of 
such studies to date, that they must rely either on unreliable candidate genes that often fail to 
replicate or on genome-wide association data that allows the identification of novel genetic variants 
but with much reduced power.   
These methods can also continue to be applied to the search for gene-environment correlations as 
in this thesis, such as following up the findings between schizophrenia and cannabis by looking at 
other illicit drugs or addictions. However to do so without any risk of confounding, greater 
information on the environmental exposures will be needed across datasets. For instance in the 
analysis of schizophrenia and cannabis use, the polygenic scores for schizophrenia were based on a 
genome-wide association study of schizophrenia that was blind to cannabis use. In this scenario the 
association with cannabis use could be due to cannabis use risk variants being picked up in the 
schizophrenia GWAS, as cases within this study are much more likely to also be users than controls. 
As such the GWAS of schizophrenia, with more cases with environmental risks for schizophrenia 
than controls, would pick up not just genetic variants that predispose directly to schizophrenia but 
also any variants that predispose to environments that increase risk to schizophrenia (assuming 
there is a heritable component to experiencing these environments). Ideally a follow up study could 
be performed where the discovery GWAS of schizophrenia had cases and controls matched on 
cannabis use, or the GWAS restricted to non-users in both groups. This would give a more definitive 
understanding of how the two traits’ genetics overlap. It may also give us an estimate of how much 
of the heritability of schizophrenia comes from genetic predisposition to deleterious environments, 
and so how much of the heritability is actually modifiable. 
Turning away from the gene-environment section of the thesis and back to the evolutionary 





effect size and frequency of ‘risk’ variants should be curtailed by the selection against them in the 
population, meaning a trait with weaker selection against it should on average have variants of 
larger effect and so be more easily identified. However in the case of depression this is clearly not 
the case, given the difficulty in robustly identifying any risk variants to date [Ripke and others 
2013b]. This could in part be due to the fact that the lack of selection is due to variants being 
beneficial in some circumstances (as seen in the analysis of fecundity of siblings of those with 
depression), meaning that many seemingly healthy controls will be carriers and reducing power to 
detect associations.  
How exactly these variants might be beneficial is currently unknown, though some possibilities are 
apparent. Most psychiatric disorders and diseases can be viewed as a quantitative trait. In 
depression there is the extreme of low mood, pessimism and social withdrawal, though it is easy to 
imagine how an overly optimistic individual could also suffer reduced fitness from misjudging real 
risks and engaging in situations or individuals that were better avoided. Given the supposed 
association with stressful life events and loss of social support, depression may to some extent 
reflect an adaptive mechanism (or at least an adaptive mechanism malfunctioning) evolved to avoid 
risks when least able to deal with them. It is also worth noting that it has long been believed that 
psychiatric disorders, particularly psychosis, may overlap in families with beneficial traits. A large 
family studies of several hundred thousand in Sweden found that individuals with bipolar disorder 
and healthy siblings of people with schizophrenia and bipolar disorder are overrepresented in 
creative professions but those with major depression and their relatives are not [Kyaga and others 
2011]. The results of this study provide support for the notion that creativity and bipolar disorder 
may co-segregate in families, however did not provide matching evidence for major depression.   
Whether such associations with beneficial traits or gene-environments will provide novel insights 





increasing existence of large population datasets with access to detailed phenotypic, environmental 
and genomics data should allow future research to explore these questions and hopefully improve 
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